pharma · Dermatomyositis · Diffuse Cutaneous Systemic Sclerosis · CRBP
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 500 River Ridge Dr, Norwood, Massachusetts 02062, US
- Founded
- 2014
- Employees
- 57
- Programs
- 11
- Drugs
- 3
- Patents
- 6
Corbus Pharmaceuticals patents
6 pharmaceutical patents indexed for Corbus Pharmaceuticals. 0 expire within 24 months.
Corbus Pharmaceuticals has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11052066
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10369131
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10154986
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10085964
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 9820964
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 9801849
Ultrapure tetrahydrocannabinol-11-oic acids
granted
Frequently asked questions
How many patents does Corbus Pharmaceuticals have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Corbus Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.